(Boursier.com) — Nicox whose resources are focused on the clinical development of the lead program, NCX 470, in glaucoma hopes to obtain primary results in the second half of 2025 from the phase 3 Denali clinical study in patients with open-angle glaucoma or hypertension ocular.
The company plans to secure funding to support the clinical development of NCX 470.
Nicox is funded through at least November 2024, focusing exclusively on the development of the NCX 470. The company is continuing discussions to enter into revenue-generating agreements, including the sale or licensing of certain assets, and is exploring several strategic options aimed at extending its cash horizon. The Company explains that it is evaluating all financing options and will select the most appropriate one when the time comes.
As of February 28, the Group’s financial debt amounted to 18.2 million, including 16.9 million of outstanding debt with Kreos Capital VI (UK) Limited, a subsidiary of BlackRock, and EUR1.3 million of loans guaranteed by the State in the context of the COVID-19 pandemic.
©2024 Boursier.com